Logo image of 2HQ.DE

TILRAY BRANDS INC (2HQ.DE) Stock Fundamental Analysis

FRA:2HQ - Deutsche Boerse Ag - US88688T1007 - Common Stock - Currency: EUR

0.348  +0.02 (+6.03%)

Fundamental Rating

2

Overall 2HQ gets a fundamental rating of 2 out of 10. We evaluated 2HQ against 51 industry peers in the Pharmaceuticals industry. 2HQ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 2HQ is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year 2HQ has reported negative net income.
2HQ had a negative operating cash flow in the past year.
2HQ had negative earnings in each of the past 5 years.
In the past 5 years 2HQ reported 4 times negative operating cash flow.
2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCF2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

1.2 Ratios

2HQ's Return On Assets of -27.79% is on the low side compared to the rest of the industry. 2HQ is outperformed by 80.39% of its industry peers.
The Return On Equity of 2HQ (-34.64%) is worse than 80.39% of its industry peers.
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
2HQ.DE Yearly ROA, ROE, ROIC2HQ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Gross Margin of 2HQ (30.88%) is worse than 80.39% of its industry peers.
2HQ's Gross Margin has declined in the last couple of years.
2HQ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
2HQ.DE Yearly Profit, Operating, Gross Margins2HQ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

2HQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 2HQ has been increased compared to 1 year ago.
The number of shares outstanding for 2HQ has been increased compared to 5 years ago.
The debt/assets ratio for 2HQ has been reduced compared to a year ago.
2HQ.DE Yearly Shares Outstanding2HQ.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
2HQ.DE Yearly Total Debt VS Total Assets2HQ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -0.81, we must say that 2HQ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.81, 2HQ is doing worse than 76.47% of the companies in the same industry.
A Debt/Equity ratio of 0.11 indicates that 2HQ is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.11, 2HQ is in the better half of the industry, outperforming 74.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.81
ROIC/WACCN/A
WACC8.39%
2HQ.DE Yearly LT Debt VS Equity VS FCF2HQ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

2HQ has a Current Ratio of 2.62. This indicates that 2HQ is financially healthy and has no problem in meeting its short term obligations.
2HQ has a better Current ratio (2.62) than 84.31% of its industry peers.
2HQ has a Quick Ratio of 1.61. This is a normal value and indicates that 2HQ is financially healthy and should not expect problems in meeting its short term obligations.
2HQ has a Quick ratio of 1.61. This is amongst the best in the industry. 2HQ outperforms 82.35% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.61
2HQ.DE Yearly Current Assets VS Current Liabilites2HQ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

2HQ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.41%, which is quite impressive.
Looking at the last year, 2HQ shows a quite strong growth in Revenue. The Revenue has grown by 11.23% in the last year.
2HQ shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.86% yearly.
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%

3.2 Future

Based on estimates for the next years, 2HQ will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.67% on average per year.
The Revenue is expected to grow by 5.68% on average over the next years.
EPS Next Y-222.48%
EPS Next 2Y17.62%
EPS Next 3Y21.07%
EPS Next 5Y18.67%
Revenue Next Year8.55%
Revenue Next 2Y7.24%
Revenue Next 3Y6.26%
Revenue Next 5Y5.68%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
2HQ.DE Yearly Revenue VS Estimates2HQ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
2HQ.DE Yearly EPS VS Estimates2HQ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

2HQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year 2HQ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2HQ.DE Price Earnings VS Forward Price Earnings2HQ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

2HQ's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.81
2HQ.DE Per share data2HQ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

2HQ's earnings are expected to grow with 21.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.62%
EPS Next 3Y21.07%

More info and screens

0

5. Dividend

5.1 Amount

2HQ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

FRA:2HQ (6/26/2025, 7:00:00 PM)

0.348

+0.02 (+6.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-08 2025-04-08/bmo
Earnings (Next)07-28 2025-07-28/amc
Inst Owners10.08%
Inst Owner ChangeN/A
Ins Owners0.31%
Ins Owner ChangeN/A
Market Cap356.88M
Analysts72.22
Price Target1.17 (236.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.2%
Min EPS beat(2)-145.1%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-85.68%
EPS beat(12)1
Avg EPS beat(12)-398.32%
EPS beat(16)4
Avg EPS beat(16)-256.75%
Revenue beat(2)0
Avg Revenue beat(2)-8.97%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-7.31%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-2.67%
Revenue beat(12)1
Avg Revenue beat(12)-3.36%
Revenue beat(16)1
Avg Revenue beat(16)-7.96%
PT rev (1m)3.7%
PT rev (3m)-38.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-150%
EPS NY rev (1m)0%
EPS NY rev (3m)-439.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.94%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-4.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.5
P/FCF N/A
P/OCF N/A
P/B 0.15
P/tB 0.72
EV/EBITDA 17.81
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.69
BVpS2.28
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.88%
FCFM N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA 12.7
Cap/Depr 27.68%
Cap/Sales 4.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.61
Altman-Z -0.81
F-Score4
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-222.48%
EPS Next 2Y17.62%
EPS Next 3Y21.07%
EPS Next 5Y18.67%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%
Revenue Next Year8.55%
Revenue Next 2Y7.24%
Revenue Next 3Y6.26%
Revenue Next 5Y5.68%
EBIT growth 1Y-239.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.02%
EBIT Next 3Y37.28%
EBIT Next 5Y23.96%
FCF growth 1Y-24.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.12%
OCF growth 3YN/A
OCF growth 5YN/A